Uniplan Investment Counsel’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-60,049
Closed -$2.9M 143
2021
Q1
$2.9M Sell
60,049
-148,817
-71% -$7.75M 0.19% 92
2020
Q4
$11.2M Sell
208,866
-49,325
-19% -$2.23M 0.77% 37
2020
Q3
$9.52M Buy
258,191
+169
+0.1% +$6.28K 0.66% 39
2020
Q2
$7.99M Sell
258,022
-4,828
-2% -$134K 0.56% 43
2020
Q1
$7.26M Buy
262,850
+35,630
+16% +$1.07M 0.55% 44
2019
Q4
$6.65M Buy
227,220
+1,585
+0.7% +$37.7K 0.39% 54
2019
Q3
$4.31M Sell
225,635
-13,033
-5% -$306K 0.27% 62
2019
Q2
$5.24M Sell
238,668
-62,301
-21% -$1.37M 0.33% 58
2019
Q1
$6.16M Sell
300,969
-319,798
-52% -$5.56M 0.39% 60
2018
Q4
$7.83M Sell
620,767
-21,771
-3% -$324K 0.54% 44
2018
Q3
$9.86M Sell
642,538
-82,056
-11% -$1.13M 0.57% 46
2018
Q2
$9.5M Sell
724,594
-140,946
-16% -$1.55M 0.46% 57
2018
Q1
$7.06M Buy
865,540
+18,057
+2% +$146K 0.33% 71
2017
Q4
$7.51M Buy
847,483
+8,173
+1% +$75.4K 0.31% 85
2017
Q3
$9.34M Buy
839,310
+55,506
+7% +$540K 0.39% 69
2017
Q2
$7.02M Sell
783,804
-125,724
-14% -$998K 0.31% 71
2017
Q1
$7.18M Buy
909,528
+45,265
+5% +$369K 0.33% 69
2016
Q4
$7.41M Sell
864,263
-21,164
-2% -$181K 0.34% 70
2016
Q3
$7.28M Buy
885,427
+16,860
+2% +$141K 0.33% 65
2016
Q2
$6.98M Buy
868,567
+46,707
+6% +$374K 0.32% 63
2016
Q1
$5.54M Buy
821,860
+2,710
+0.3% +$17.8K 0.27% 72
2015
Q4
$6.45M Sell
819,150
-97,202
-11% -$712K 0.31% 66
2015
Q3
$5.25M Sell
916,352
-34,853
-4% -$216K 0.25% 74
2015
Q2
$5.15M Buy
+951,205
New +$4.91M 0.23% 90

Other funds holding NEO

Uniplan Investment Counsel's NEO Position: Q2 2021 in Review

Uniplan Investment Counsel sold out of NeoGenomics (NEO) in Q2 2021, closing a stake of 60,049 shares — an estimated $2.9M sold.

Uniplan Investment Counsel first reported a position in NEO in Q2 2015 and held it in 24 quarters. The position peaked at $11.2M in Q4 2020. 311 funds tracked by Wall St. Rank hold NEO as of Q2 2021.

  • Uniplan Investment Counsel reported no remaining NeoGenomics position as of Q2 2021 after selling out during the quarter.
  • Uniplan Investment Counsel sold 60,049 NeoGenomics shares in Q2 2021, an estimated $2.9M.
  • Uniplan Investment Counsel first reported a position in NeoGenomics in Q2 2015 and held it in 24 quarters.
  • Uniplan Investment Counsel's NeoGenomics position peaked at $11.2M in Q4 2020.
  • 311 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2021.

Based on Uniplan Investment Counsel's 13F filing for Q2 2021, filed 13 Aug 2021.